Task Force on sudden cardiac death of the European Society of Cardiology

European Heart Journal

Volumn 22, Issue 16, 2001, Pages 1374-1450

  Priori, S G ^a   Aliot, E ^a   Blomstrom Lundqvist, C ^a   Bossaert, L ^a   Breithardt, G ^a   Brugada, P ^a   Camm, A J ^a   Cappato, R ^a   Cobbe, S M ^a   Di Mario, C ^a   Maron, B J ^a   McKenna, W J ^a   Pedersen, A K ^a   Ravens, U ^a   Schwartz, P J ^a   Trusz Gluza, M ^a   Vardas, P ^a   Wellens, H J J ^a   Zipes, D P ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIHISTAMINIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; ENCAINIDE; FIBRINOLYTIC AGENT; FLECAINIDE; HEPARIN; INOTROPIC AGENT; MAGNESIUM; NEUROLEPTIC AGENT; NITRIC ACID DERIVATIVE; POLYUNSATURATED FATTY ACID; POTASSIUM CHANNEL BLOCKING AGENT; PROKINETIC AGENT; SODIUM CHANNEL BLOCKING AGENT;

AORTA STENOSIS; ARTICLE; ATRIOVENTRICULAR BLOCK; BRUGADA SYNDROME; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEFIBRILLATOR; EUROPE; HEART DILATATION; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LONG QT SYNDROME; MEDICAL SOCIETY; MITRAL VALVE PROLAPSE; MYOCARDITIS; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; RESUSCITATION; SECONDARY PREVENTION; SINUS NODE DYSFUNCTION; SUDDEN DEATH; THORAX INJURY; TORSADE DES POINTES; WOLFF PARKINSON WHITE SYNDROME;

ALGORITHMS; AORTIC VALVE STENOSIS; ARRHYTHMIA; ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA; CARDIOMYOPATHY, DILATED; CARDIOMYOPATHY, HYPERTROPHIC; DEATH, SUDDEN, CARDIAC; HEART FAILURE, CONGESTIVE; HUMANS; LONG QT SYNDROME; MITRAL VALVE PROLAPSE; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; RESUSCITATION; RISK FACTORS; TORSADES DE POINTES; WOLFF-PARKINSON-WHITE SYNDROME;

EID: 17944381537     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2824     Document Type: Article

References (586)

1. Cardiac arrest and sudden cardiac death
2. Clinical classification of cardiac deaths
3. Exploration of the precision of classifying sudden cardiac death. Implications for the interpretation of clinical trials
4. Mode of death in chronic heart failure. A request and proposition for more accurate classification
5. Community study of the causes of 'natural' sudden death
6. Acute ischaemic lesions in death due to ischaemic heart disease. An autopsy study of 333 cases of out-of-hospital death
7. Validation of death certificate diagnosis of out-of-hospital coronary heart disease deaths in Olmsted County, Minnesota
8. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death
9. Proceedings: Emergency medical care system. Lincoln (Beb) mobile heart team
10. The paramedic ambulance: A Canadian experience
11. A study of out-of-hospital cardiac arrests in northeastern Minnesota
12. Incidence of cardiac arrest: A neglected factor in evaluating survival rates
13. The burden of cardiovascular diseases mortality in Europe
14. Out-of-hospital cardiac arrest in the 1990's: A population-based study in the Maastricht area on incidence, characteristics and survival
15. Sudden cardiac death. Structure, function, and time-dependence of risk
16. Sudden coronary death in the United States: 1980-1985
17. Incidence and prognosis of unrecognized myocardial infarction. An update on the Framingham study
18. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population
19. Long- and short-term risk of sudden coronary death
20. Risk factors for sudden cardiac death in middle-aged British men
21. Risk factors for sudden unexpected cardiac death in Tasmanian men
22. Predicting sudden death in the population: The Paris Prospective Study I
23. Epidemiology of sudden coronary death: Population at risk
24. Heart rate variability from 24-hour electrocardiography and the 2-year risk for sudden death
25. Heart rate, ischaemic heart disease, and sudden cardiac death in middle-aged British men
26. Hypertension, antihypertensive treatment, and sudden coronary death. The Framingham Study
27. Blood pressure and isolated systolic hypertension and the risk of coronary heart disease and mortality in elderly men (the Zutphen Elderly Study)
28. Left ventricular hypertrophy as a risk factor: The Framingham experience
29. Anatomic substrate differences between black and white victims of sudden cardiac death: Hypertension, coronary artery disease, or both?
30. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death
31. Overview of the outcome trials in older patients with isolated systolic hypertension
32. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context
33. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
34. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study
35. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II)
36. Fish consumption and risk of sudden cardiac death
37. Plaque rupture and sudden death related to exertion in men with coronary artery disease
38. Leisure-time physical activity and the risk of primary cardiac arrest
39. Alcohol and exercise in myocardial infarction and sudden coronary death in men and women
40. Alcohol intemperance and social disability as risk factors for different causes of death
41. QT prolongation and sudden cardiac death in patients with alcoholic liver disease
42. Risk indicators for out-of-hospital cardiac arrest in patients with coronary artery disease
43. High heart rate: A risk factor for cardiovascular death in elderly men
44. Heart rate variability from short electrocardiographic recordings predicts mortality from all causes in middle-aged and elderly men. The Zutphen Study
45. Sudden death: Lessons from subsets in population studies
46. Risk factors for sudden coronary death in the United States
47. Comparison of sudden and non-sudden coronary deaths in the United States
48. Smoking as a risk factor for recurrence of sudden cardiac arrest
49. Sudden death, impaired glucose tolerance, and diabetes in Japanese American men
50. Risk factors for sudden and non-sudden coronary death
51. Prognostic value of ischemic electrocardiographic findings for cardiovascular mortality in men and women
52. T-loop morphology as a marker of cardiac events in the elderly
53. Dispersion of ventricular repolarization and refractoriness
54. QT interval prolongation predicts cardiovascular mortality in an apparently healthy population
55. Association between QT interval and coronary heart disease in middle-aged and elderly men. The Zutphen Study
56. QTc dispersion predicts cardiac mortality in the elderly: The Rotterdam Study
57. QT dispersion as a risk factor for sudden cardiac death and fatal myocardial infarction in a coronary risk population
58. Family history as a risk factor for primary cardiac arrest
59. Ambulatory electrocardiographic recordings at the time of fatal cardiac arrest
60. Mechanism of death and prevalence of myocardial ischemic symptoms in the terminal event after acute myocardial infarction
61. Prevalence, characteristics and prognostic value during long-term follow-up of non-sustained ventricular tachycardia after myocardial infarction in the thrombolytic era
62. Use of ventricular premature complexes for risk stratification after acute myocardial infarction in the thrombolytic era
63. Sudden coronary death. Frequency of active coronary lesions, inactive coronary lesions, and myocardial infarction
64. Ventricular fibrillation resulting from ischemia at a site remote from previous myocardial infarction. A conscious canine model of sudden coronary death
65. Incidence of coronary thrombosis in sudden death due to coronary artery disease
66. Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic death
67. Ambulatory sudden cardiac death: Mechanisms of production of fatal arrhythmia on the basis of data from 157 cases
68. Survivors of prehospital cardiac arrest
69. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure
70. Sudden death in hospitalized patients: Cardiac rhythm disturbances detected by ambulatory electrocardiographic monitoring
71. Sudden death during long-term ambulatory monitoring
72. Cardiac arrest recorded on ambulatory electrocardiograms
73. Prevalence, circumstances, mechanisms, and risk stratification of sudden cardiac death in unipolar single-chamber ventricular pacing
74. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)
75. Arrhythmias and sudden death in heart failure: Can we prevent them?
76. Acute coronary findings at autopsy in heart failure patients with sudden death: Results from the assessment of treatment with lisinopril and survival (ATLAS) trial
77. Arrhythmias and mortality in congestive heart failure
78. Left ventricular ejection fraction in the trombolytic era remains a powerful predictor of long-term but not short-term all-cause, cardiac and arrhythmic mortality after myocardial infarction - A secondary meta-analysis of 2828 patients
79. Should survivors of myocardial infarction with low ejection fraction be routinely referred to arrhythmia specialists?
80. Predictive power of increased heart rate versus depressed left ventricular ejection fraction and heart rate variability for risk stratification after myocardial infarction. Results of a two-year follow-up study
81. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction
82. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction
83. The prognostic value of predischarge quantitative two-dimensional echocardiographic measurements and the effects of early lisinopril treatment on left ventricular structure and function after acute myocardial infarction in the GISSI-3 Trial
84. Prevalence and prognostic significance of ventricular arrhythmias after acute myocardial infarction in the fibrinolytic era. GISSI-2 results
85. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram
86. Value of signal-averaged electrocardiography, radionuclide ventriculography, Holter monitoring and clinical variables for prediction of arrhythmic events in survivors of acute myocardial infarction in the thrombolytic era
87. What is the best predictor of spontaneous ventricular tachycardia and sudden death after myocardial infarction?
88. The cost-effectiveness of automatic implantable cardiac defibrillators: Results from MADIT. Multicenter Automatic Defibrillator Implantation Trial
89. A randomized study of the prevention of sudden death in patients with coronary artery disease
90. Can the MADIT results be applied to myocardial infarction patients at hospital discharge?
91. Predicting arrhythmic events after acute myocardial infarction using the signal-averaged electrocardiogram
92. Effects of thrombolytic therapy administered 6 to 24 hours after myocardial infarction on the signal-averaged ECG. Results of a multicenter randomized trial
93. Effect of thrombolytic therapy on the predictive value of signal-averaged electrocardiography after acute myocardial infarction
94. Risk stratification for malignant arrhythmic events in patients with an acute myocardial infarction: Role of an open infarct-related artery and the signal-averaged ECG
95. ACC consensus document on signal-averaged electrocardiography
96. Prognostic significance of heart rate variability in post-myocardial infarction patients in the fibrinolytic era. The GISSI-2 results
97. Depressed heart rate variability identifies postinfarction patients who might benefit from prophylactic treatment with amiodarone: A substudy of EMIAT (The European Myocardial Infarct Amiodarone Trial)
98. Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction
99. QT interval prolongation as predictor of sudden death in patients with myocardial infarction
100. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest
101. Assessment of QT dispersion for prediction of mortality or arrhythmic events after myocardial infarction: Results of a prospective, long-term follow-up study
102. T wave alternans as a predictor of recurrent ventricular tachyarrhythmias in ICD recipients: Prospective comparison with conventional risk markers
103. Combined assessment of T-wave alternans and late potentials used to predict arrhythmic events after myocardial infarction. A prospective study
104. Risk stratification after myocardial infarction
105. Arrhythmia risk: Electrophysiological studies and monophasic action potentials
106. Predictors of arrhythmic death and cardiac arrest in the ESVEM trial. Electrophysiologic Study Versus Electromagnetic Monitoring
107. Risk stratification following myocardial infarction in the thrombolytic era: A two-step strategy using noninvasive and invasive methods
108. Open infarct artery, late potentials, and other prognostic factors in patients after acute myocardial infarction in the thrombolytic era. A prospective trial
109. Prognostic value of thrombolysis, coronary artery patency, signal-averaged electrocardiography, left ventricular ejection fraction, and Holter electrocardiographic monitoring for life-threatening ventricular arrhythmias after a first acute myocardial infarction
110. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial
111. Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials
112. Acute myocardial infarction: Pre-hospital and in-hospital management
113. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: Systematic overview of individual data from 100,000 patients in randomized trials
114. Interobserver discordance in the classification of mechanisms of death in studies of heart failure
115. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure
116. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
117. Adjunctive drug therapy of acute myocardial infarction - Evidence from clinical trials
118. Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials
119. The effect of spironolactone on morbidity and mortality in patients with severe heart failure
120. Effect of statins on risk of coronary disease. A meta-analysis of randomized controlled trials
121. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial
122. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients
123. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
124. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial
125. Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis
126. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: Systematic overview of randomised trials
127. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: A quantitative review
128. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction
129. Long-term ACE-inhibitor therapy in patients with heart failure or left ventricular dysfunction: A systematic overview of data from individual patients
130. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
131. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction
132. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial
133. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction
134. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction
135. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
136. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)
137. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the Randomized Aldactone Evaluation Study (RALES)
138. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
139. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
140. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
141. The results of the GISSI-Prevenzione trial in the general framework of secondary prevention
142. Effect of intravenous nitrates on mortality in acute myocardial infarction: An overview of the randomised trials
143. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction
144. Role of magnesium in reducing mortality in acute myocardial infarction. A review of the evidence
145. Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: The second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2)
146. Randomized trials of magnesium in acute myocardial infarction: Big numbers do not tell the whole story
147. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
148. Effects of alteplase in acute myocardial infarction: 6-Month results from the ASSET study. Anglo-Scandinavian Study of Early Thrombolysis
149. A prospective trial of intravenous streptokinase in acute myocardial infarction (I.S.A.M.). Mortality, morbidity, and infarct size at 21 days
150. Long-term effects of intravenous anistreplase in acute myocardial infarction: Final report of the AIMS study
151. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin
152. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction
153. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
154. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial
155. Thrombolytic therapy for acute myocardial infarction. A review
156. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
157. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients
158. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction
159. The effect of warfarin on mortality and reinfarction after myocardial infarction
160. A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction
161. Effect of coronary artery bypass graft surgery on survival: Overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration
162. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study
163. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: The FRISC II invasive randomised trial
164. Infarct artery perfusion and changes in left ventricular volume in the month after acute myocardial infarction
165. Coronary recanalization by elective angioplasty prevents ventricular dilation after anterior myocardial infarction
166. Myocardial infarction redefined - A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction
167. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention
168. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: A report from the Second National Registry of Myocardial Infarction (NRMI-2)
169. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: In-hospital and 30-day results of the PAMI stent pilot trial
170. A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction
171. Coronary angioplasty with or without stent implantation for acute myocardial infarction
172. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction
173. Effect of glycoprorein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction
174. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction
175. Role of myocardial revascularization in sudden cardiac death
176. Incidence of implantable defibrillator discharges after coronary revascularization in survivors of ischemic sudden cardiac death
177. Effect of oral milrinone on mortality in severe chronic heart failure
178. The effect of digoxin on mortality and morbidity in patients with heart failure
179. The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms
180. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction
181. Effects of prophylactic lidocaine in suspected acute myocardial infarction. An overview of results from the randomized, controlled trials
182. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials
183. Beta blockade during and after myocardial infarction: An overview of the randomized trials
184. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: The CAPRICORN randomised trial
185. Effect of beta-blockade on mortality in patients with heart failure: A meta-analysis of randomized clinical trials
186. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
187. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomised trials
188. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction
189. Dofetilide in patients with congestive heart failure and left ventricular dysfunction
190. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: A randomized trial
191. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction
192. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial
193. Effect of propranolol in postinfarction patients with mechanical or electrical complications
194. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction
195. Beta-blockade after myocardial infarction
196. Beta-blockade after myocardial infarction: Systematic review and meta regression analysis
197. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
198. Beta-blockers in heart failure
199. The Beta-Blocker Pooling Project (BBPP): Subgroup findings from randomized trials in post infarction patients
200. Safety and efficacy of carvedilol in severe heart failure
201. Effects of beta blockers on ventricular dysfunction after myocardial infarction: Tolerability and survival effects
202. Beta-blockers and sudden cardiac death
203. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction
204. Physician use of beta-adrenergic blocking therapy: A changing perspective
205. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction
206. Amiodarone: Reevaluation of an old drug
207. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT
208. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT
209. Morbidity and mortality following early administration of amiodarone in acute myocardial infarction
210. Effect of amiodarone on mortality after myocardial infarction: A double-blind, placebo-controlled, pilot study
211. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS)
212. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure
213. Randomised trial of low-dose amiodarone in severe congestive heart failure
214. Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA)
215. Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: A placebo-controlled trial
216. Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. A substudy of EMIAT (the European Myocardial Infarct Amiodarone Trial)
217. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias
218. Efficacy and safety of d,1-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest
219. Calcium channel blockers in acute myocardial infarction and unstable angina: An overview
220. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II - DAVIT II)
221. A controlled clinical trial to assess the effect of a calcium channel blocker on the progression of coronary atherosclerosis
222. Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies
223. Termination of malignant ventricular arrhythmias with an implanted automatic defibrillator in human beings
224. The automatic implantable cardioverter-defibrillator in drug-refractory ventricular tachyarrhythmias
225. Long-term outcome with the automatic implantable cardioverter-defibrillator
226. Efficacy of the automatic implantable cardioverter-defibrillator in prolonging survival in patients with severe underlying cardiac disease
227. Predictors of first discharge and subsequent survival in patients with automatic implantable cardioverter-defibrillators
228. Usefulness of the automatic implantable cardioverter defibrillator in improving survival of patients with severely depressed left ventricular function associated with coronary artery disease
229. Survival after implantation of the cardioverter defibrillator
230. Implantable transvenous cardioverter-defibrillators
231. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia
232. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery
233. Prevalence, characteristics and significance of ventricular premature complexes and ventricular tachycardia detected by 24-hour continuous electrocardiographic recording in the Cardiac Arrhythmia Suppression Trial
234. Non-sustained ventricular tachycardia in patients with coronary artery disease: Role of electrophysiologic study
235. Electrophysiological testing and non-sustained ventricular tachycardia. Use and limitations in patients with coronary artery disease and impaired ventricular function
236. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction
237. Baroreflex sensitivity, clinical correlates, and cardiovascular mortality among patients with a first myocardial infarction. A prospective study
238. Comparison of d,1-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease
239. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study)
240. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias
241. Canadian implantable defibrillator study (CIDS): A randomized trial of the implantable cardioverter defibrillator against amiodarone
242. Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH)
243. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials
244. Radiofrequency catheter ablation of ventricular tachycardia in patients with coronary artery disease
245. Identification of reentry circuit sites during catheter mapping and radiofrequency ablation of ventricular tachycardia late after myocardial infarction
246. Left ventricular segmental wall motion score as a criterion for selecting patients for direct surgery in the treatment of postinfarction ventricular tachycardia
247. Continuation of antiarrhythmic drugs, or arrhythmia surgery after multiple drug failures. A randomized trial in the treatment of post-infarction ventricular tachycardia
248. Undocumented syncope with inducible ventricular tachycardia is as malignant as documented symptomatic ventricular tachycardia/fibrillation. A Canadian Implantable Defibrillator Study (CIDS) subgroup analysis
249. 'Stable' ventricular tachycardia is not a benign rhythm: Insights from the Antiarrhythmics Versus Implantable Defibrillators (AVID) Registry
250. Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias
251. Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy: The Canadian Implantable Defibrillator Study
252. Implantable cardioverter defibrillator therapy: The sickest patients benefit the most
253. The management of hypertrophic cardiomyopathy
254. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults
255. Prevalence of hypertrophic cardiomyopathy in an outpatient population referred for echocardiographic study
256. Hypertrophic cardiomyopathy
257. Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review
258. Occurrence and significance of progressive left ventricular wall thinning and relative cavity dilatation in hypertrophic cardiomyopathy
259. Prognosis in hypertrophic cardiomyopathy: Role of age and clinical, electrocardiographic and haemodynamic features
260. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy
261. Hypertrophic cardiomyopathy: An important cause of sudden death
262. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatient population
263. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort
264. Hypertrophic cardiomyopathy in Tuscany: Clinical course and outcome in an unselected regional population
265. Sudden death in young competitive athletes. Clinical, demographic, and pathological profiles
266. Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy
267. Implications of left ventricular remodeling in hypertrophic cardiomyopathy
268. Properties of mutant contractile proteins that cause hypertrophic cardiomyopathy
269. Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy
270. Utility of cardiopulmonary exercise in the assessment of clinical determinants of functional capacity in hypertrophic cardiomyopathy
271. Sudden death in hypertrophic cardiomyopathy: A profile of 78 patients
272. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy
273. Relation between severity of left ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy
274. Sudden death in hypertrophic cardiomyopathy: Identification of high risk patients
275. A new mutation of the cardiac troponin T gene causing familial hypertrophic cardiomyopathy without left ventricular hypertrophy
276. Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy
277. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy
278. Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy
279. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy
280. Arrhythmia in hypertrophic cardiomyopathy. I: Influence on prognosis
281. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: A prospective study
282. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and non-sustained ventricular tachycardia
283. The prognostic significance of non-sustained ventricular tachycardia in hypertrophic cardiomyopathy
284. Prognostic determinants in hypertrophic cardiomyopathy. Prospective evaluation of a therapeutic strategy based on clinical, Holter, haemodynamic, and electrophysiological findings
285. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest
286. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy
287. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy
288. Programmed electrical stimulation in hypertrophic cardiomyopathy. Results in patients with and without cardiac arrest or syncope
289. The significance of paced electrogram fractionation in hypertrophic cardiomyopathy. A prospective study
290. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy
291. Assessment of QT dispersion as a prognostic marker for sudden death in a regional nonreferred hypertrophic cardiomyopathy cohort
292. Ambulatory assessment of the QT interval in patients with hypertrophic cardiomyopathy: Risk stratification and effect of low dose amiodarone
293. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia
294. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: Assessment in an unselected non-referral based patient population
295. Epidemiology of hypertrophic cardiomyopathy-related death; revisited in a large non-referral-based patients population
296. Right ventricular dysplasia: A report of 24 adult cases
297. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies
298. Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy
299. Sudden unexpected nontraumatic death in 54 young adults: A 30-year population-based study
300. Right ventricular dysplasia associated with sudden death in young adults
301. Screening for hypertrophic cardiomyopathy in young athletes
302. Undetected cardiac lesions cause unexpected sudden cardiac death during occasional sport activity. A report of 80 cases
303. The gene for arrhythmogenic right ventricular cardiomyopathy maps to chromosome 14q23-q24
304. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease)
305. Progressive ECG changes in arrhythmogenic right ventricular disease. Evidence for an evolving disease
306. Arrhythmogenic right ventricular cardiomyopathy in young versus adult patients: Similarities and differences
307. Characteristics and outcome in arrhythmogenic right ventricular dysplasia
308. Right ventricular cardiomyopathy: Diffuse dilatation, focal dysplasia or biventricular disease
309. A long term follow up of 15 patients with arrhythmogenic right ventricular dysplasia
310. Long-term follow-up in patients with arrhythmogenic right ventricular disease
311. Spectrum of clinico-pathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: A multicenter study
312. Familial occurrence of right ventricular dysplasia: A study involving nine families
313. QT dispersion in patients with arrhythmogenic right ventricular dysplasia
314. Mapping of ventricular repolarization potentials in patients with arrhythmogenic right ventricular dysplasia: Principal component analysis of the ST-T waves
315. Late potentials and ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy
316. Late potentials in arrhythmogenic right ventricular dysplasia. Prevalence, diagnostic and prognostic values
317. Value of quantitative measurement of signal-averaged electrocardiographic variables in arrhythmogenic right ventricular dysplasia: Correlation with echocardiographic right ventricular cavity dimensions
318. Familial incidence of late ventricular potentials and electrocardiographic abnormalities in arrhythmogenic right ventricular dysplasia
319. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia
320. Nonischemic sustained ventricular tachycardia: Clinical outcome in 12 patients with arrhythmogenic right ventricular dysplasia
321. Left ventricular impairment in arrhythmogenic right ventricular dysplasia: What we can learn from angiography
322. Right ventricular cardiomyopathy and sudden death in young people
323. Sudden death in young competitive athletes: Clinicopathologic correlations in 22 cases
324. Characteristics, prognosis and treatment of the ventricular arrhythmias of right ventricular dysplasia
325. Determinants of spontaneous occurrence of sustained monomorphic ventricular tachycardia in right ventricular dysplasia
326. Pathology of arrhythmogenic right ventricular cardiomyopathy/dysplasia - An autopsy study of 20 forensic cases
327. Cardiac arrest and sudden death in competitive athletes with arrhythmogenic right ventricular dysplasia
328. Catheter ablation of ventricular tachycardia in patients with right ventricular dysplasia: Identification of target sites by entrainment mapping techniques
329. Entrainment mapping and radiofrequency catheter ablation of ventricular tachycardia in right ventricular dysplasia
330. Arrhythmogenic right ventricular dysplasia: Clinical results with implantable cardioverter defibrillators
331. Implantable cardioverter defibrillator therapy in patients with arrhythmogenic right ventricular cardiomyopathy, long QT syndrome, or no structural heart disease
332. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984
333. The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy
334. Familial dilated cardiomyopathy in the United Kingdom
335. The natural history of idiopathic dilated cardiomyopathy
336. Changing mortality in dilated cardiomyopathy
337. Idiopathic dilated cardiomyopathy
338. Variation in mode of sudden cardiac death in patients with dilated cardiomyopathy
339. Sudden death in idiopathic dilated cardiomyopathy
340. Good prognosis for dilated cardiomyopathy without severe heart failure or arrhythmia
341. Mode of death in idiopathic dilated cardiomyopathy: A multivariate analysis of prognostic determinants
342. Predictors of sudden death in idiopathic dilated cardiomyopathy
343. Predictors of total mortality and sudden death in mild to moderate heart failure
344. Prognostic guides in patients with idiopathic or ischemic dilated cardiomyopathy assessed for cardiac transplantation
345. Diagnostic value of ventricular stimulation in patients with idiopathic dilated cardiomyopathy
346. Syncope in advanced heart failure: High risk of sudden death regardless of origin of syncope
347. Outcome of patients with nonischemic dilated cardiomyopathy and unexplained syncope treated with an implantable defibrillator
348. Idiopathic dilated cardiomyopathy. Role of programmed electrical stimulation and Holter monitoring in predicting those at risk of sudden death
349. Significance of ventricular arrhythmias in idiopathic dilated cardiomyopathy
350. Evaluation and treatment of nonsustained ventricular tachycardia
351. Treatment of cardiac insufficiency: Does treatment depend on whether its cause is ischemic or idiopathic?
352. Dilated cardiomyopathy versus coronary artery disease in patients with VT/VF: Differences in presentation and outcome in the arrhythmics versus implantable defibrillators (AVID) registry
353. The long QT syndrome
354. Genetic and molecular basis of cardiac arrhythmias; impact on clinical management
355. Genetic and molecular basis of cardiac arrhythmias: Impact on clinical management part III
356. Genetic and molecular basis of cardiac arrhythmias: Impact on clinical management parts I and II
357. Age- and sex-related differences in clinical manifestations in patients with congenital long-QT syndrome: Findings from the International LQTS Registry
358. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome
359. Low penetrance in the long-QT syndrome: Clinical impact
360. The long QT syndrome. Prospective longitudinal study of 328 families
361. Dispersion of the QT interval. A marker of therapeutic efficacy in the idiopathic long QT syndrome
362. Electrical alternation of the T-wave: Clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long QT syndrome
363. T wave alternans in idiopathic long QT syndrome
364. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome
365. Influence of genotype on the clinical course of the long-QT syndrome
366. Genotype-phenotype correlation in the long-QT syndrome: Gene-specific triggers for life-threatening arrhythmias
367. Long QT syndrome associated with syndactyly identified in females
368. Electrophysiologic testing in patients with the long QT syndrome
369. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias
370. Idiopathic long QT syndrome: Progress and questions
371. Left cardiac sympathetic denervation in the therapy of congenital long QT syndrome. A worldwide report
372. Efficacy of permanent pacing in the management of high-risk patients with long QT syndrome
373. Long-term follow-up of patients with long-QT syndrome treated with beta-blockers and continuous pacing
374. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome. A multicenter report
375. Right bundle-branch block and ST-segment elevation in leads V1 through V3: A marker for sudden death in patients without demonstrable structural heart disease
376. Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome: A prospective evaluation of 52 families
377. Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent
378. Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts
379. Catecholaminergic-induced severe ventricular arrhythmias with Adams-Stokes syndrome in children: Report of four cases
380. Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients
381. Control of multiform ventricular tachycardia by propranolol in a child with no identifiable cardiac disease and sudden death
382. Clinical and electrophysiological characteristics of ventricular tachycardia in children with normal hearts
383. Arrhythmic disorder mapped to chromosome 1q42-q43 causes malignant polymorphic ventricular tachycardia in structurally normal hearts
384. Effects of tetrodotoxin, lidocaine, verapamil, and AHR-2666 on Ouabain-induced delayed after depolarizations in canine Purkinje fibers
385. Cardiac intracellular calcium release channels: Role in heart failure
386. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia
387. Aortic stenosis
388. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic and exercise predictors of outcome
389. The natural history of aortic valve stenosis
390. The natural history of adults with asymptomatic, haemodynamically significant aortic stenosis
391. Mortality and worsening of prognostic profile during waiting time for valve replacement in aortic stenosis
392. Sudden cardiac death while wearing a Holter monitor
393. Sites of conduction disease in aortic stenosis: Significance of valve gradient and calcification
394. QT dispersion is reduced after valve replacement in patients with aortic stenosis
395. Prevalence of late potentials in adult aortic stenosis
396. Increased QT dispersion and other repolarization abnormalities as a possible cause of electrical instability in isolated aortic stenosis
397. Patients with valvular heart disease presenting with sustained ventricular tachyarrhythmias or syncope: Results of programmed ventricular stimulation and long-term follow-up
398. Commentary
399. Reduction in sudden late death by concomitant revascularization with aortic valve replacement
400. Influence of aortic valve replacement on sudden death in patients with pure aortic stenosis
401. Sudden cardiac death after aortic valve surgery: Incidence and concomitant factors
402. Death and other time-related events after valve replacement
403. Atrioventricular conduction abnormalities in patients undergoing isolated aortic or mitral valve replacement
404. Permanent cardiac stimulation after aortic valve replacement: Incidence, predictive factors and long-term prognosis
405. ACC/AHA Guidelines for the clinical application of echocardiography. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in colloboration with the American Society of Echocardiography
406. Prevalence and clinical outcome of mitral-valve prolapse
407. Clinical course of 470 patients with mitral valve prolapse
408. Natural history of mitral valve prolapse
409. Malignant ventricular arrhythmias in patients with mitral valve prolapse and mild mitral regurgitation
410. Sudden death in young people with apparently isolated mitral valve prolapse
411. Echocardiographically documented mitral-valve prolapse. Long-term follow-up of 237 patients
412. Mitral valve prolapse: Cardiac arrest with long-term survival
413. Ventricular arrhythmia factors in mitral valve prolapse
414. Ventricular arrhythmias in syndrome of balloon deformity of mitral valve. Definition of possible high risk group
415. Increased dispersion of refractoriness in the absence of QT prolongation in patients with mitral valve prolapse and ventricular arrhythmias
416. Significance of QT dispersion on ventricular arrhythmias in mitral valve prolapse
417. Mitral valve prolapse in the general population. 1. Epidemiologic features: The Framingham Study
418. Normal and anomalous coronary arteries: Definitions and classification
419. Anomalous aortic origin of coronary arteries
420. Aberrant coronary artery origin from the aorta. Report of 18 patients, review of literature and delineation of natural history and management
421. Anomalous coronary arteries: Location, degree of atherosclerosis and effect on survival - A report from the Coronary Artery Surgery Study
422. Sudden death as a complication of anomalous left coronary origin from the anterior sinus of Valsalva, A not-so-minor congenital anomaly
423. Anomalous origin of the left coronary artery from the pulmonary artery: Report of an adult with ventricular fibrillation as the presenting symptom
424. Anomalous left coronary artery from the pulmonary artery: A 15 year sample
425. Diagnosis of anomalous left coronary artery by Doppler color flow mapping: Distinction from other causes of dilated cardiomyopathy
426. The role of transesophageal echocardiography in identifying anomalous coronary arteries
427. Myocardial bridging as an isolated angiographic change in the anterior descending branch of the left coronary artery
428. The significance of myocardial bridge upon atherosclerosis in the left anterior descending coronary artery
429. New signs characteristic of myocardial bridging demonstrated by intracoronary ultrasound and Doppler
430. Fatal outcome associated with autopsy proven myocardial bridging of the left anterior descending coronary artery
431. Myocardial bridging on the left anterior descending coronary artery and sudden death. Apropos of 19 cases with autopsy
432. Myocardial bridging in a young patient with sudden death
433. Myocardial bridging in a survivor of sudden cardiac near-death: Role of intracoronary doppler flow measurements and angiography during dobutamine stress in the clinical evaluation
434. Myocardial bridging in children with hypertrophic cardiomyopathy - A risk factor for sudden death
435. Functional, angiographic and intracoronary Doppler flow characteristics in symptomatic patients with myocardial bridging: Effect of short-term intravenous betablocker medication
436. Coronary stenting in the management of myocardial ischaemia caused by muscle bridging
437. Modified supra-arterial myotomy for intermittent coronary obstruction by myocardial bridges
438. Aborted sudden death in the Wolff-Parkinson-White syndrome
439. A population study of the natural history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953-1989
440. Ventricular pre-excitation in the general population: A study on the mode of presentation and clinical course
441. Ventricular fibrillation in the Wolff-Parkinson-White syndrome
442. The predictive value of electrophysiologic studies in untreated patients with Wolff-Parkinson-White syndrome
443. Ventricular fibrillation in Wolff-Parkinson-White syndrome. Predictive factors
444. Ventricular fibrillation in the Wolff-Parkinson-White syndrome
445. Use of ajmaline in patients with the Wolff-Parkinson-White syndrome to disclose short refractory period of the accessory pathway
446. Lack of prognostic value of syncope in patients with Wolff-Parkinson-White syndrome
447. Electrophysiological characteristics of asymptomatic Wolff-Parkinson-White syndrome
448. Prognostic value of electrophysiology testing in asymptomatic patients with Wolff-Parkinson-White pattern
449. Guidelines for clinical intracardiac electrophysiological and catheter ablation procedures. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Intracardiac Electrophysiologic and Catheter Ablation Procedures), developed in collaboration with the North American Society of Pacing and Electrophysiology
450. Sudden death recorded during Holter monitoring
451. Sudden death during ambulatory Holter monitoring
452. Cardiac pacing in the world: A survey of the state of the art in 1986
453. Survival in sinoatrial disorder (sick-sinus syndrome)
454. Long-term pacing in sinus node disease: Effects of stimulation mode on cardiovascular morbidity and mortality
455. Use of an extended monitoring strategy in patients with problematic syncope
456. Long-term follow-up of patients from a randomised trial of atrial versus ventricular pacing for sick-sinus syndrome
457. Bundle branch block and sudden death
458. Natural history of 'high-risk' bundle-branch block: Final report of a prospective study
459. The significance of second degree atrioventricular block and bundle branch block. Observations regarding site and type of block
460. Recommendations for pacemaker prescription for symptomatic bradycardia. Report of a working party of the British Pacing and Electrophysiology Group
461. Survival in second degree atrioventricular block
462. Complete heart block. A clinical, haemodynamic and pharmacological study in patients with and without an artificial pacemaker
463. Natural history of chronic second-degree atrioventricular nodal block
464. Prognosis of patients with complete heart block or arrhythmic syncope who were not treated with artificial pacemakers. A long-term follow-up study of 101 patients
465. The clinical significance of bundle branch block complicating acute myocardial infarction. 2. Indications for temporary and permanent pacemaker insertion
466. Sudden death in patients with chronic bifascicular block
467. Significance of left axis deviation in patients with chronic left bundle branch block
468. Electrophysiologic evaluation of syncope in patients with bifascicular block
469. Electrophysiologic testing in bundle branch block and unexplained syncope
470. Clinical implications of electrophysiology study findings in patients with chronic bifascicular block and syncope
471. Significance of block distal to the His bundle induced by atrial pacing in patients with chronic bifascicular block
472. Role of invasive electrophysiologic testing in patients with symptomatic bundle branch block
473. Prophylactic permanent pacemakers for patients with chronic bundle branch block
474. Value of the H-Q interval in patients with bundle branch block and the role of prophylactic permanent pacing
475. Electrophysiologic effects of procaine amide in patients with intraventricular conduction delay
476. Intermittent atrioventricular block: Procainamide administration as a provocative test
477. Complete atrioventricular block complicating inferior wall acute myocardial infarction treated with reperfusion therapy
478. Prognostic significance of second-degree atrioventricular block in inferior wall acute myocardial infarction
479. Incidence and prognostic implications of heart block complicating inferior myocardial infarction treated with thrombolytic therapy: Results from TIMI II
480. The incidence and mortality of intraventricular conduction defects in acute myocardial infarction
481. Long-term prognosis after acute anterior infarction with atrioventricular block
482. A simplified method to predict occurrence of complete heart block during acute myocardial infarction
483. Congenital complete heart block in patients without anatomic cardiac defects
484. Isolated congenital complete atrioventricular block in adult life. A prospective study
485. Congenital complete heart block: An international study of the natural history
486. Congenital complete heart block associated with QT prolongation
487. Bradycardia-mediated tachyarrhythmias in congenital heart disease and responses to chronic pacing at physiologic rates
488. Sudden cardiac death in cardiac transplant recipients
489. Natural history, determinants, and clinical relevance of conduction abnormalities following orthotopic heart transplantation
490. Ventricular fibrillation and sudden death after radiofrequency catheter ablation of the atrioventricular junction
491. Torsades de pointes following radiofrequency catheter His ablation
492. Rapid rates during bradycardia prolong ventricular refractoriness and facilitate ventricular tachycardia induction with cesium in dogs
493. 26th Bethesda conference: Recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: Hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse
494. Sudden death in young athletes. Lessons from the Hank Gathers affair
495. Cardiovascular risks to young persons on the athletic field
496. Competitive athletes with cardiovascular disease - The case of Nicholas Knapp
497. Incidence of death during jogging in Rhode Island from 1975 through 1980
498. The incidence of primary cardiac arrest during vigorous exercise
499. Risk for sudden cardiac death associated with marathon running
500. Prevalence of sudden cardiac death during competitive sports activities in Minnesota high school athletes
501. Nontraumatic sports death in high school and college athletes
502. Sports-related and non-sports-related sudden cardiac death in young adults
503. Sudden death from cardiac causes in children and young adults
504. Non-traumatic death in joggers. A series of 30 patients at autopsy
505. Causes of sudden death in competitive athletes
506. Cardiac disease in young trained athletes. Insights into methods for distinguishing athlete's heart from structural heart disease, with particular emphasis on hypertrophic cardiomyopathy
507. The upper limit of physiologic cardiac hypertrophy in highly trained elite athletes
508. Physiologic left ventricular cavity dilatation in elite athletes
509. Athlete's heart in women. Echocardiographic characterization of highly trained elite female athletes
510. Anomalous origin of either the right or left main coronary artery from the aorta without coursing of the anomalistically arising artery between aorta and pulmonary trunk
511. Clinical profile of congenital coronary artery anomalies with origin from the wrong aortic sinus leading to sudden death in young competitive athletes
512. Preparticipation cardiovascular evaluation of the competitive athlete: Perspectives from the 30-year Italian experience
513. Cardiovascular preparticipation screening of competitive athletes. A statement for health professionals from the Sudden Death Committee (clinical cardiology) and Congenital Cardiac Defects Committee (cardiovascular disease in the young), American Heart Association
514. Profile of preparticipation cardiovascular screening for high school athletes
515. Preparticipation cardiovascular screening for collegiate student-athletes
516. Impact of laboratory molecular diagnosis on contemporary diagnostic criteria for genetically transmitted cardiovascular diseases: Hypertrophic cardiomyopathy, long-QT syndrome, and Marfan syndrome. A statement for healthcare professionals from the Councils on Clinical Cardiology, Cardiovascular Disease in the Young, and Basic Science, American Heart Association
517. Role of the implantable cardioverter defibrillator in patients with idiopathic ventricular fibrillation. Data from the UCARE international registry
518. Idiopathic ventricular fibrillation
519. Electrocardiographic identification of abnormal ventricular depolarization and repolarization in patients with idiopathic ventricular fibrillation
520. Cardiac 123I-MIBG uptake in idiopathic ventricular tachycardia and fibrillation
521. Idiopathic ventricular tachycardia and fibrillation
522. Sudden cardiac death in Air Force recruits. A 20-year review
523. Isolated myocardial fibrosis as a cause of sudden cardiac death and its possible relation to myocarditis
524. Myocarditis as a cause of sudden death response
525. Myocarditis caused by Chlamydia pneumoniae (TWAR) and sudden unexpected death in a Swedish elite orienteer
526. Tracheal aspirate as a substrate for polymerase chain reaction detection of viral genome in childhood pneumonia and myocarditis
527. Ventricular pre-excitation in children and young adults: Atrial myocarditis as a possible trigger of sudden death
528. Blunt impact to the chest leading to sudden death from cardiac arrest during sports activities
529. Clinical profile of commotio cordis: An under appreciated cause of sudden death in the young during sports and other activities
530. The clinical spectrum of commotio cordis: The first 100 cases from the U.S. Registry
531. An experimental model of sudden death due to low-energy chest-wall impact (commotio cordis)
532. Selective activation of the K(+)(ATP) channel is a mechanism by which sudden death is produced by low-energy chest-wall impact (Commotio cordis)
533. Survival following blunt chest impact-induced cardiac arrest during sports activities in young athletes
534. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology
535. Drug-induced torsade de pointes: From molecular biology to bedside
536. Amiodarone and torsade de pointes
537. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone
538. Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy
539. Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: Possible mechanism for terfenadine-associated cardiotoxicity
540. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole
541. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin
542. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram
543. Risk of developing life-threatening ventricular arrhythmia associated with terfenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine
544. Cardiac actions of antihistamines
545. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes
546. QT interval prolongation and cardiac arrest during antibiotic therapy with spiramycin in a newborn infant
547. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes
548. QT prolongation and paroxysmal ventricular tachycardia occurring during fever following trimethoprimsulfamethoxazole administration
549. QT prolongation and torsades de pointes after administration of trimethoprim-sulfamethoxazole
550. A common polymorphism associated with antibiotic-induced cardiac arrhythmia
551. Quinolone-induced QT interval prolongation: A not-so-unexpected class effect
552. Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers
553. Pharmacogenetic phenotyping and genotyping. Present status and future potential
554. Inhibition of rat liver microsomal cytochrome P-450 steroid hydroxylase reactions by imidazole antimycotic agents
555. Blockade of HERG and Kv1.5 by ketoconazole
556. Quinine and quinidine: A comparison of EKG effects during the treatment of malaria
557. A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males
558. Cardiac effects of antimalarial treatment with halofantrine
559. Patterns of change in the electrocardiogram after halofantrine treatment of acute uncomplicated falciparum in children
560. The pharmacokinetics and electrocardiographic effects of chloroquine in healthy subjects
561. Torsade de pointe. Malignant cardiac arrhythmia induced by amantadine poisoning
562. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 Cases in Finland
563. Torsade de pointes and low-dose oral haloperidol
564. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: A review of the literature
565. Death of two subjects due to imipramine and desipramine metabolite accumulation during chronic therapy: A review of the literature and possible mechanisms
566. Cisapride and fatal arrhythmia
567. Withdrawal of troglitazone and cisapride
568. Resuscitation in Europe: A tale of five European regions
569. Outcomes of rapid defibrillation by security officers after cardiac arrest in casinos
570. Survival after cardiac arrest outside hospital in Sweden
571. Survey of 3765 cardiopulmonary resuscitations in British hospitals (the BRESUS Study): Methods and overall results
572. Pre-CPR conditions and the final outcome of CPR
573. Outcome of CPR in a large metropolitan area - Where are the survivors?
574. Standards for cardiopulmonary resuscitation (CPR) and emergency cardiac care (ECC)
575. Advisory statements of the International Liaison Committee on Resuscitation
576. International 2000 Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care: International consensus on science
577. A study of chest compression rates during cardiopulmonary resuscitation in humans. The importance of rate-directed chest compressions
578. Multicenter, randomized, controlled trial of 150-J biphasic shocks compared with 200- to 360-J monophasic shocks in the resuscitation of out-of-hospital cardiac arrest victims
579. Recommended guidelines for reviewing, reporting, and conducting research on in-hospital resuscitation: The in-hospital 'Utstein style'. A statement for healthcare professionals from the American Heart Association, the European Resuscitation Council, the Heart and Stroke Foundation of Canada, the Australian Resuscitation Council, and the Resuscitation Councils of Southern Africa
580. High discharge survival rate after out-of-hospital ventricular fibrillation with rapid defibrillation by police and paramedics
581. Use of automated external defibrillators by police officers for treatment of out-of-hospital cardiac arrest
582. An airline cardiac arrest program
583. Defibrillation aboard a commercial aircraft
584. Public access defibrillation. A statement for healthcare professionals from the American Heart Association Task Force on Automatic External Defibrillation